Starter Functional Antibodies

• Blocking : PD-1, PD-L1 (in vivo)
• Neutralizing : TH1, TH2, TH17, iTreg induction and differentiation (in vitro)
• Activating : CD3⁺CD28 for T-cell stimulation (in vivo & in vitro)
• Depleting : Targeted cell depletion (in vivo)

Anti-PD-1/PD-L1 blocking and neutralizing antibodies (in vivo)

Blocking and neutralizing antibodies for TH1, TH2, TH17, and iTreg induction and differentiation (in vitro)

CD3+CD28 T cell stimulation antibodies (in vivo and in vitro)

Depletion antibodies for target cell death (in vivo)

References：Mariottini A, Muraro PA and Lünemann JD (2022) Antibody_x0002_mediated cell depletion therapies in multiple sclerosis.Front. Immunol. 13:953649. doi:10.3389/fimmu.2022.953649

Notable targets for cell depletion

Case Description in Literature

References：Boivin, G., Faget, J., Ancey, PB. et al. Durable and controlled depletion of neutrophils in mice. Nat Commun 11, 2762 (2020). https://doi.org/10.1038/s41467-020-16596-9